Hey there, bargain hunter.

Let me ask you something. When a company sells a drug that just crossed one million patients in its first quarter on the market, captures 65% of new U.S. prescriptions in its category, and still grows its core obesity business at 22% — why is the stock down nearly 30% over the past year?

That is the question sitting at the center of the Novo Nordisk (NVO) opportunity right now. And the answer, when you unpack it, tells you a lot about how markets work — and where perception and reality have drifted apart.

What Happened

NVO shares trade around $49 as of early July 2026. The 52-week range stretches from $35.12 to $71.80. At the peak last year, this was one of the most celebrated pharmaceutical companies on earth — the company behind Ozempic and Wegovy, the drugs that reshaped how the world thinks about obesity medicine.

Then the market shifted. Drug pricing reform fears accelerated. The Most-Favored-Nation framework and expected list price cuts for Wegovy and Ozempic rattled investors. CagriSema, a next-generation combination therapy, missed its primary endpoint in the REDEFINE 4 obesity trial. Currency headwinds hit reported numbers. And the stock fell hard — about 29% from a year ago and well below the consensus analyst target of $47.32.

Here is the thing, though. The business kept performing.

What the Business Is Actually Doing

Novo Nordisk has built one of the most defensible drug franchises in modern pharmaceutical history. The company’s GLP-1 platform — spanning diabetes, obesity, and a growing list of adjacent indications — is not a one-product story. It is a compounding research engine with deep clinical data, regulatory relationships, and manufacturing infrastructure that takes years to replicate.

The Wegovy pill launch is the most important near-term data point. In Q1 FY2026, the oral version of semaglutide generated $2.26 billion in a single quarter — its first full quarter commercially. CEO Mike Doustdar described it as the most efficacious GLP-1 tablet now used by more than one million patients since its January launch. It captured 65% of new U.S. prescriptions in the oral GLP-1 category. That is not a struggling drug. That is a category-defining one.

Obesity care as a segment grew 22% at constant exchange rates in Q1. Management raised 2026 guidance after the results. The board funded a DKK 15 billion share buyback program running through February 2027. Free cash flow yield sits in the high teens. These are not the numbers of a company whose best days are behind it.

Why the Market Discounted It

Three things happened in sequence and the market did what markets do — it extrapolated all of them to their worst-case conclusions simultaneously.

• Pricing reform fear: U.S. list price cuts of roughly 50% for Wegovy and roughly 35% for Ozempic are expected effective January 2027 under the Most-Favored-Nation framework. That is real pressure. It is not, however, the end of the franchise. In exchange, these therapies become eligible for Medicare and Medicaid coverage — programs that insure approximately 120 million Americans — which expands the addressable patient population significantly.
• Pipeline miss: CagriSema missed its primary endpoint in the REDEFINE 4 trial. Investor reaction was sharp. But Novo’s pipeline is not a single product. Zenagamtide, a next-generation amylin combination therapy, generated strong efficacy in mid-stage studies and is entering Phase 3 in 2026. The pipeline is still active.
• Currency headwinds: Constant exchange rate growth looks very different from reported numbers when the Danish krone and U.S. dollar diverge. Markets often conflate the two.

Slight tangent, but it matters: the healthcare sector broadly has been punished by policy uncertainty since late 2024. Policy uncertainty has dominated the sector for much of the past year, producing some of the lowest relative price-to-earnings ratios in the sector’s history. When an entire sector sells off for regulatory reasons, individual franchises — even excellent ones — get dragged down regardless of their specific exposure. That dynamic creates opportunity for investors willing to separate the headline from the fundamentals.

Is It Actually Cheap?

This is where it gets interesting.

NVO currently trades at a free cash flow yield in the high teens. For a company with a dominant global GLP-1 franchise, proven obesity drug volume, and a growing pipeline, that is a remarkably undemanding valuation. The market is essentially pricing in the worst version of the pricing reform outcome and the worst version of pipeline execution at the same time.

Compare that to where the stock traded twelve months ago — above $70 — when the same underlying franchise existed, but enthusiasm was running ahead of reality. Today, pessimism may be running ahead of reality in the opposite direction.

What would need to go right for the thesis to work? Volume. If the oral Wegovy pill continues to grow at the pace it showed in Q1, higher volume can partially offset lower per-unit pricing. Management has already raised guidance once this year. That is not the behavior of a team expecting a collapse.

The Cheap Investor Scorecard

Bull, Base, and Bear

• Bull case: Wegovy pill volume continues its Q1 trajectory. Medicare and Medicaid coverage dramatically expands the patient pool. Zenagamtide Phase 3 data impresses. The market re-rates NVO toward historical multiples. Investors who bought near $49 look back at this as one of the cleaner opportunities in large-cap pharma over the past decade.
• Base case: Pricing reform compresses near-term cash flow, but volume growth partially offsets it. The stock finds a floor in the $45 to $55 range and grinds higher as pipeline clarity improves into 2027. Total return, including the buyback and any dividend, is respectable but not spectacular over a two-year hold.
• Bear case: U.S. pricing cuts are steeper than guided. Volume disappoints. Additional pipeline trials miss. The stock drifts back toward the low $30s, where it sat at its 52-week trough. This is the scenario the current price seems to partially reflect — which is precisely what makes this worth examining carefully.

What to Watch

• Q2 earnings report arrives pre-market on August 5, 2026. Consensus is at $0.83 EPS. Watch oral Wegovy prescription trends and obesity care segment growth in constant exchange rate terms.
• Final clarity on U.S. Most-Favored-Nation price cut timelines and exact percentages under the January 2027 implementation.
• Zenagamtide Phase 3 trial initiation and early data signals in late 2026 or early 2027.
• Medicare and Medicaid coverage rollout pace for Wegovy — this is the volume offset that makes the pricing math more tolerable.
• Any M&A or licensing activity that could add pipeline depth beyond GLP-1.

The Bottom Line

Novo Nordisk is not a broken company. It is a great company in a difficult regulatory environment — which is a different thing entirely.

The market has decided that pricing reform and one pipeline miss are enough to mark down the world’s leading obesity drug franchise by nearly 30%. The Cheap Investor thinks that is too severe a verdict. If the oral Wegovy pill volume continues at its Q1 pace, and if Medicare and Medicaid access unlocks a broader patient base, the math on per-unit price cuts becomes much more manageable.

If the thesis is wrong — if pricing cuts bite harder than expected, or if volume disappoints in Q2 — the downside is real. The stock has already demonstrated it can trade in the mid-$30s. That risk is not trivial and should be sized accordingly.

But if it is right? You are buying one of the most consequential drug platforms in modern medicine at a price that assumes the worst.

That is usually a reasonable place to start looking.

Until next time,
The Cheap Investor Editorial Team